Carregant...
Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
BACKGROUND: It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. METHODS AND RESULTS: We administered 100 mg of cana...
Guardat en:
| Publicat a: | Diabetol Metab Syndr |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5628447/ https://ncbi.nlm.nih.gov/pubmed/29034006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13098-017-0275-4 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|